Smith & Nephew plc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while State Street SPDR S&P Homebuilders ETF trades at $99.14. The key difference: Smith & Nephew plc pays a 2.85% dividend while State Street SPDR S&P Homebuilders ETF pays none, and State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | XHB | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $38.53 | $121.36 |
52-Week Low | $27.80 | $94.86 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
XHB trades at $100.75, down 2.42% today amid bearish technical signals. The ETF shows neutral oscillators but bearish moving averages, with support at $98-$100 and resistance at $102-$105. Recent housing data shows mixed signals with new home sales rising 1.6% in June (Census Bureau, June 2026) while existing home sales declined 2.4% (WSJ, July 9, 2026).
The homebuilding sector faces headwinds from high mortgage rates and record home prices, though institutional interest remains with Greenland Capital's $17.33 million investment (Defense World, September 7, 2026). Key catalysts include housing affordability legislation and potential market rebound opportunities.
Trailing returns across standard periods
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →